Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive.
Under the order, first announced in February 2016, the companies are required to
divest two dosage strengths of generic doxycycline monohydrate capsules, which are used to treat bacterial infections, and generic mesalamine extended release capsules, which are used to treat ulcerative colitis.
The Commission vote approving the final order was 3-0. (FTC File No. 151 0202; the staff contact is Kari A. Wallace, Bureau of Competition, 202-326-3085)
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.
WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…
WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…
Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…
WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…
WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…
WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…